Specialised Therapeutics Australia Pty Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Specialised Therapeutics Australia Pty Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013238
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Specialised Therapeutics Australia Pty Ltd (STA) is a biopharmaceutical company that develops and commercializes therapies and technologies for unmet medical needs. The company’s product portfolio includes abraxane, gliolan, oncotype dx, iclusig, oncotype dx prostate and aloxi. Its pipeline products comprise anamorelin and iluvien, among others. STA also offers services such as pharmacovigilance, investigator sponsored clinical trials, warehousing and distribution, commercialisation and marketing and local document filing, regulatory approval and registration. The company’s target therapy areas include oncology, hematology, urology, CNS and endocrinology. It partners international partner companies. The company markets its products across Australia and New Zealand. STA is headquartered in Melbourne, Victoria, Australia.

Specialised Therapeutics Australia Pty Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Specialised Therapeutics Australia Pty Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Specialised Therapeutics Australia Pty Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Specialised Therapeutics Australia Pty Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Specialised Therapeutics Australia Pty Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Specialised Therapeutics Australia Pty Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Specialised Therapeutics Australia Pty Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Specialised Therapeutics Australia Pty Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Alimera Sciences Enters Into Distribution Agreement With Specialised Therapeutics For Iluvien 12
Ariad Pharma Enters Into Agreement With Specialised Therapeutics To Commercialize Iclusig In Australia 13
Licensing Agreements 14
Puma Biotechnology Enters into Licensing Agreement with Specialised Therapeutics 14
Specialised Therapeutics Asia Enters into Licensing Agreement with Pharma Mar 15
Aeterna Zentaris Enters into Licensing Agreement with Specialised Therapeutics Asia 16
Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 17
Mundipharma Enters into Licensing Agreement with Specialized Therapeutics 18
Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 19
Helsinn Healthcare Enters Into Licensing Agreement With Specialised Therapeutics Australia For Anamorelin 20
Optimer Pharma Enters Into Licensing Agreement With Specialised Therapeutics For Fidaxomicin 22
Helsinn Enters Into Licensing Agreement With Specialised Therapeutics 23
Specialised Therapeutics Australia Enters Into Licensing Agreement With photonamic For Gliolan 24
Specialised Therapeutics Australia Pty Ltd – Key Competitors 25
Specialised Therapeutics Australia Pty Ltd – Key Employees 26
Specialised Therapeutics Australia Pty Ltd – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
Specialised Therapeutics Australia Pty Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Specialised Therapeutics Australia Pty Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Specialised Therapeutics Australia Pty Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Specialised Therapeutics Australia Pty Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Specialised Therapeutics Australia Pty Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Specialised Therapeutics Australia Pty Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Specialised Therapeutics Australia Pty Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Alimera Sciences Enters Into Distribution Agreement With Specialised Therapeutics For Iluvien 12
Ariad Pharma Enters Into Agreement With Specialised Therapeutics To Commercialize Iclusig In Australia 13
Puma Biotechnology Enters into Licensing Agreement with Specialised Therapeutics 14
Specialised Therapeutics Asia Enters into Licensing Agreement with Pharma Mar 15
Aeterna Zentaris Enters into Licensing Agreement with Specialised Therapeutics Asia 16
Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 17
Mundipharma Enters into Licensing Agreement with Specialized Therapeutics 18
Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 19
Helsinn Healthcare Enters Into Licensing Agreement With Specialised Therapeutics Australia For Anamorelin 20
Optimer Pharma Enters Into Licensing Agreement With Specialised Therapeutics For Fidaxomicin 22
Helsinn Enters Into Licensing Agreement With Specialised Therapeutics 23
Specialised Therapeutics Australia Enters Into Licensing Agreement With photonamic For Gliolan 24
Specialised Therapeutics Australia Pty Ltd, Key Competitors 25
Specialised Therapeutics Australia Pty Ltd, Key Employees 26
Specialised Therapeutics Australia Pty Ltd, Subsidiaries 27

★海外企業調査レポート[Specialised Therapeutics Australia Pty Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Ig Group Holdings Plc:企業の戦略・SWOT・財務分析
    Ig Group Holdings Plc - Strategy, SWOT and Corporate Finance Report Summary Ig Group Holdings Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Centrais Eletricas do Para SA (CELP5):電力:M&Aディール及び事業提携情報
    Summary Centrais Eletricas do Para SA (CELPA), a subsidiary of Equatorial Energia SA is an electric utility that supplies and distributes power and electricity. The utility offers services such as electric metering, online bill payment, surge protection, outage reporting, energy saving tips, rebates …
  • Marquette Capital Partners LLC:企業の戦略・SWOT・財務情報
    Marquette Capital Partners LLC - Strategy, SWOT and Corporate Finance Report Summary Marquette Capital Partners LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Peak Resources Ltd. (PEK):企業の財務・戦略的SWOT分析
    Peak Resources Ltd. (PEK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Tata Consultancy Services Limited:戦略・SWOT・企業財務分析
    Tata Consultancy Services Limited - Strategy, SWOT and Corporate Finance Report Summary Tata Consultancy Services Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Qiagen Marseille SA-医療機器分野:企業M&A・提携分析
    Summary Qiagen Marseille SA (HalioDx), formerly Ipsogen SA is a subsidiary of Qiagen NV, a drugs manufacturing company that develops and markets molecular diagnostic tests. The company offers products for the treatment of chronic myeloid, chronic lymphocytic, acute myeloid, and acute lymphoblastic l …
  • Reliance Industries Ltd (RELIANCE):石油・ガス:M&Aディール及び事業提携情報
    Summary Reliance Industries Ltd (RIL) is a conglomerate with business interests in energy, petrochemicals, textiles, retail, and telecommunication sectors. The company carries out exploration, development and production of oil and gas, refining of crude oil, marketing of petroleum products, and prod …
  • TX Holdings Inc (TXHG):企業の財務・戦略的SWOT分析
    Summary TX Holdings Inc (TX Holdings) is a diversified company. The company provides rail products and mining supplies. It offers rail products such as rail, rail chart, turnouts, track accessories, tools, and others. TX Holdings provides mining supplies such as miner bits, roof bit assemblies, bloc …
  • Skechers U.S.A., Inc. (SKX):企業の財務・戦略的SWOT分析
    Skechers U.S.A., Inc. (SKX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • UCB Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary UCB Inc (UCB), a subsidiary of UCB SA, is a healthcare solutions provider that offers therapeutics. The company develops products with an emphasis on central nervous system and immunology therapeutic domains. Its products include cimzia, vimpat, keppra XR, neupro, tussionex pennkinetic, meta …
  • Thryv Holdings Inc (THRY):企業の財務・戦略的SWOT分析
    Thryv Holdings Inc (THRY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Mead Johnson Nutrition Co:企業の戦略的SWOT分析
    Mead Johnson Nutrition Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • RedHill Biopharma Ltd (RDHL):製薬・医療:M&Aディール及び事業提携情報
    Summary RedHill Biopharma Ltd (RedHill) is a biopharmaceutical company that develops and commercializes therapeutics in the areas of gastroenterology (GI) and cancer. The company’s commercial product portfolio consists of Donnatal for IBS and acute enterocolitis; Esomeprazole Strontium Delayed-Relea …
  • GR. Sarantis S.A.:企業の戦略・SWOT・財務情報
    GR. Sarantis S.A. - Strategy, SWOT and Corporate Finance Report Summary GR. Sarantis S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • HORNBACH Holding AG & Co. KGaA:企業の戦略・SWOT・財務情報
    HORNBACH Holding AG & Co. KGaA - Strategy, SWOT and Corporate Finance Report Summary HORNBACH Holding AG & Co. KGaA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Burgan Bank Sak:企業の戦略・SWOT・財務分析
    Burgan Bank Sak - Strategy, SWOT and Corporate Finance Report Summary Burgan Bank Sak - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • China Railway Signal & Communication Corp Ltd:企業の戦略・SWOT・財務情報
    China Railway Signal & Communication Corp Ltd - Strategy, SWOT and Corporate Finance Report Summary China Railway Signal & Communication Corp Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, opera …
  • MetaStat Inc (MTST):医療機器:M&Aディール及び事業提携情報
    Summary MetaStat Inc (MetaStat) is a biotechnology company that discovers and develops personalized diagnostic and therapeutic treatment solutions for cancer patients. The company develops therapeutic product candidates based on novel approach that offers intracellular Mena protein isoforms drugable …
  • McCarthy & Stone Plc:企業の戦略・SWOT・財務分析
    McCarthy & Stone Plc - Strategy, SWOT and Corporate Finance Report Summary McCarthy & Stone Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Ei Towers SpA:企業の戦略・SWOT・財務情報
    Ei Towers SpA - Strategy, SWOT and Corporate Finance Report Summary Ei Towers SpA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆